Research Article
A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients
Table 3
Disease and treatment specific baseline characteristics.
| | Tumor disease characteristics |
Frequency (percentage) or mean (min–max) | | Viscum | Etoposide |
| | Time since primary diagnosis (years) | 4.0 (1.5–10.5) | 3.7 (1.4–7.2) | | DFS 1° interval (months) | 22.3 (2.9–43.3) | 27.9 (14.5–39.4) | | DFS 2° interval (months) | 22.9 (3.0–82.1) | 14.9 (1.8–47.4) | | Time since 2° relapse (weeks) | 13.9 (0.9–76.6) | 7.6 (1.9–24.6) | | Osteosarcoma | | | | Chondrosarcomatous | 1 (11.1) | 2 (18.2) | | Osteoblastic | 4 (44.4) | 5 (45.5) | | Spindle cell sarcoma | 0 | 1 (9.1) | | Not otherwise specified | 4 (44.4) | 3 (27.3) | | Staging (Enneking) | | | | I (I B) | 0 | 1 (9.1) | | II (II A, II B) | 6 (66.7) | 8 (72.7) | | III (III, III A, III B) | 3 (33.3) | 2 (18.2) | | Grading | | | | 2 | 8 (88.9) | 11 (100) | | 3 | 1 (11.1) | — | | 4 | — | — | | Metastases present | 9 (100) | 11 (100) | | 2nd chemotherapy after 1st relapse | 5 (55.6) | 4 (36.4) | | Time since last chemotherapy (years) | 3.0 (0.6–10.5) | 2.8 (0.4–7.2) | | Radiotherapy | — | — | | Frequency of surgeries | | | | 3 | 5 (55.6) | 9 (81.8) | | 4 | 3 (33.3) | 1 (9.1) | | 5 | 1 (11.1) | 1 (9.1) | | Time since last surgery (months) | 1.5 (0.7–2.0) | 2.2 (1.2–5.9) |
|
|
